$Cassava Sciences (SAVA.US)$ NEW SAVA BULLISH PRESS RELEASE ...
$Cassava Sciences (SAVA.US)$ NEW SAVA BULLISH PRESS RELEASE “Cassava is pleased to put this matter behind us,” Mr. Barry said. “We can now focus all of our attention on completion of the ongoing Phase 3 trials of simufilam. While no one can accurately predict the future, we remain hopeful that the trials will be successful and that, after a rigorous FDA review, simufilam could become available to help those suffering from Alzheimer’s disease.”
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
101682201-dna : This 40m is expected